SGS
VRTX icon

Sterling Global Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Sterling Global Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,830
Closed -$200K – 31
2017
Q1 		$200K Buy
+1,830
New +$161K 0.97% 26

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sterling Global Strategies's VRTX Position: Q2 2017 in Review

Sterling Global Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 1,830 shares — an estimated $200K sold.

Sterling Global Strategies first reported a position in VRTX in Q1 2017 and held it in 1 quarter. The position peaked at $200K in Q1 2017. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • Sterling Global Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sterling Global Strategies sold 1,830 Vertex Pharmaceuticals shares in Q2 2017, an estimated $200K.
  • Sterling Global Strategies first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Sterling Global Strategies's Vertex Pharmaceuticals position peaked at $200K in Q1 2017.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Sterling Global Strategies's 13F filing for Q2 2017, filed 2 Aug 2017.